Pulmatrix (PULM) Narrows Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pulmatrix Reports Q2 2016 Financial Results
August 4, 2016 8:31 AM EDTLEXINGTON, Mass., Aug. 4, 2016 /PRNewswire/ --Â Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline.
"In the first half of the year, we continued to build awareness around our proprietary iSPERSETM inhaled drug delivery platform and communicate how we believe this... More
